

DALE B. SCHENK et al.
Application No.: 09/724,552
Page 3

PATENT

REMARKS/ARGUMENTS

Applicants have added new claims 69-71. Support for new claims 69-71 is found throughout the specification, e.g., page 18, lines 25-29. Thus, the new claims raise no new matter.

Applicant elects the following species:

Species 1B: humanized antibodies;

Species 2B: monoclonal antibodies;

Species 3A: IgG1; and,


Species 4B: antibodies that bind to an epitope within residues 1-5 of A β .

Claims 47 and 67-71 read on humanized antibodies (species 1B); monoclonal antibodies (species 2B), and IgG1 (species 3A). Claims 47, 67-68, 69 and 71 read on antibodies that bind to an epitope within residues 1-5 of A β (species 4B).

Applicants maintain the traverse of the requirement to elect a species of Group 4.

Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,


Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:lah
PA 3290983 v1